EVENTS

2024/05/02
ƒ[ƒuƒ‰ƒtƒBƒbƒVƒ…“Ő«Œ€‹†‚Ι‚¨‚―‚ιŽ”ˆη•iŽΏŠΗ—‚̏d—v«

2024/05/01
high-throughput individual zebrafish screening

2024/04/26
ƒ[ƒuƒ‰ƒtƒBƒbƒVƒ…‘n–ς‚Μ’·Š‚Ζ‰Ϋ‘θ

2024/04/25
discovery of stanniocalcin1 as cardiotoxic defence gene

2024/04/24
Tumour Angiogenesis in Patient-Deriveved Xenograft Zebarafish Model

tdiscovery of stanniocalcin1 as cardiotoxic defence gene

                     
2024/04/25

We have discovered stanniocalcin1 as cardiotoxic defence gene in 2015. the potential clinical applications of stanniocalcin in oncocardiology include its use as a biomarker for cancer therapy-induced cardiotoxicity, its potential as a therapeutic target for cardioprotection, and its role in regulating calcium homeostasis, which may be relevant for managing calcium-related cardiovascular complications in cancer patients.

ŠΦ˜AƒŠƒ“ƒN

ŽOd‘εŠw‘εŠw‰@ˆγŠwŒnŒ€‹†‰ΘƒVƒXƒeƒ€ƒY–ς—Šw

ŽOd‘εŠwƒƒfƒBƒJƒ‹ƒ[ƒuƒ‰ƒtƒBƒbƒVƒ…Œ€‹†ƒZƒ“ƒ^[

ŠΦ˜Aƒtƒ@ƒCƒ‹

discovery of stanniocalcin1 as cardiotoxic defence gene

high-throughput screening for cardiotoxicology